Investor's Business Daily on MSN
Why this biotech, up 12% since its breakout, yo-yoed on a key FDA development
Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious ...
Myricx is working on a new "family" of antibody-drug conjugates, which have become an important part of cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results